Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Bal Pharma Limited

NSE: BALPHARMAPharmaceuticalsTrade-to-trade true

Share price

₹93.06

-3.27% close of 9 Oct 2026

Market cap ₹152 CrP/E 19.2 (as of 8 Oct 2026)

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 7 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

57

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹152 Cr

P/E ratio

19.2

P/B ratio

1.9

ROCE

9.8%

ROE

7.8%

Dividend yield

1.2%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹114.4552-week low ₹60.42

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 13.5% over the past year, and 5.7% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 7.6% to 10.0% over the last four years.

Whether it grew faster than its sector

It grew 5.7% a year against a sector median of 13.1% — 7.4 percentage points slower.

Room to re-rate, or risk of de-rating

At 19.2× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 47.7×, across 5 companies. It is against its own five-year median of 31.7×, the 10th percentile of its own range.

Whether growth justifies the valuation

Priced at 0.5 times its growth rate, on earnings growth of 35%.

Profit growthPrice per ₹1 profitPer 1% growth
Bal Pharma Limited — this one35%/yr19.2×₹0.55
Jubilant Pharmova Limited47%/yr38.4×₹0.82
AstraZeneca Pharma India Limited15%/yr84.1×₹5.6
Marksans Pharma Limited16%/yr26.8×₹1.7
Concord Biotech Limited0%/yr47.7×—
Sudeep Pharma Limited40%/yr67.1×₹1.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 88 of 130 on returns, 99 of 127 on growth, 99 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 9.8% on capital, ahead of 32% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹99 crore of cash from the business, spent ₹75 crore on plant and equipment, and returned ₹12 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 554 arrived as cash — well above the profit; depreciation and interest are the reason, not a windfall. Its cash comes back faster than it used to: it went from being waiting 18 days for its cash to waiting 4 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

6 of 8 checks clear · 75%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 12 Aug 2026 · Consolidated · Unaudited

Revenue

₹89 Cr

Revenue vs last year

+34.5%

Revenue vs last quarter

+5.4%

Net profit

₹1 Cr

Profit vs last year

+441.8%

Profit vs last quarter

-68.4%

Net margin

1.3%

EPS

₹0.71

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹152 Cr
Prev close
₹93.06
52w High
₹125
52w Low
₹60.0
Enterprise value
₹305 Cr
Beta
0.8
Price CAGR 1y
19.0%
Price CAGR 3y
2.0%
Price CAGR 5y
-2.0%
Price CAGR 10y
-1.0%

Ratios

Return on assets
1.6%
PEG ratio
0.6
P/E ratio
19.2
P/B ratio
1.9
EV / EBITDA
9.8
Industry P/E
38.0
ROCE
9.8%
ROCE 5y average
10.8%
ROE
7.8%
Debt / Equity
2.0
Interest coverage
1.4
Dividend yield
1.2%
ROE 3y average
9.0%
ROE last year
8.0%

Annual P&L

Annual revenue
₹312 Cr
Annual profit
₹6 Cr
Operating margin
10.0%
Net profit margin
1.9%
EBITDA margin
10.3%
Sales growth 3y
0.9%
Sales growth 5y
4.4%
Profit growth 3y
35.0%
Profit growth 5y
6.0%
EPS
₹3.9
Sales growth TTM
14.0%
Profit growth TTM
1.0%
Dividend payout
30.0%

Quarter P&L

Sales latest quarter
₹89 Cr
Profit latest quarter
₹1 Cr
YoY quarterly sales growth
34.5%
YoY quarterly profit growth
438.1%
OPM latest quarter
9.0%

Balance Sheet

Book Value
₹51.3
Face Value
₹10.0
Total debt
₹160 Cr
Total cash
₹7 Cr
Borrowings
₹160 Cr
Reserves / Equity
4.1

Cash Flow

Operating cash flow
₹31 Cr
Free cash flow
₹9 Cr
FCF yield
-5.5%
Net cash flow
₹1 Cr

Shareholding

Promoter holding
50.9%
FII holding
0.1%
DII holding
—
Public holding
49.0%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.94,28,0570.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.52,54,6650.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.31,79,1640.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,14,9630.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.31,10,6990.10362.1125.52,026.329.117.8
Cipla1,327.2029.91,06,9970.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.71,03,8760.04574.129.64,030.612.913.5
Bal Pharma98.6221.61561.221.1460.088.634.59.8
Median417.9034.42,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales70938295747473826674888489
Expenses64857485686665746068787481
Material Cost393640444148
Change in Inventories-1.70-6.47-2.140.61-4.23-0.23
Purchases of Stock-in-Trade6.973.981.782.041.422.91
Employee Cost151516171817
Other Expenses151112151712
Operating Profit6.447.707.799.606.477.697.757.646.065.739.54117.95
OPM %9.158.329.54108.7010119.339.207.7411138.97
Other Income0.160.140.102.450.82-0.200.511.080.721.120.33-0.240.44
Exceptional items (within Other Income)000000
Interest3.643.823.664.144.243.655.013.954.053.864.854.064.47
Depreciation2.532.422.962.162.432.482.692.182.522.273.233.062.78
Profit before tax0.431.601.275.750.621.360.562.590.210.721.793.221.14
Tax %7939333.6558247.14-109000-120
Net Profit0.090.970.855.530.261.040.525.410.210.721.793.601.13
EPS in Rs0.050.610.563.460.160.650.303.410.130.451.122.250.70
Diluted EPS in Rs3.400.130.451.122.260.71

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales187198229211225171251281304339303312334
Expenses170183214194207166226257279308273280301
Material Cost150161
Change in Inventories-7.05-12
Purchases of Stock-in-Trade159.23
Employee Cost6266
Other Expenses5355
Operating Profit1715151718525242531303234
OPM %976882.9010989101010
Other Income1132121513222
Exceptional items (within Other Income)00
Interest7689131312111215171717
Depreciation7767681099109.771111
Profit before tax5333-0-144959.055.145.937
Tax %259011487-1,175-5-15384518-41-7
Net Profit41-002-135637.457.246.327
EPS in Rs2.821.101.241.962.67-8.623.203.781.644.684.533.944.52
Diluted EPS in Rs4.563.95
Dividend Payout %35918151370312661262630

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
5%
5 years
4%
3 years
1%
TTM
14%

Compounded profit growth

10 years
16%
5 years
6%
3 years
35%
TTM
1%

Stock price CAGR

10 years
-1%
5 years
-2%
3 years
2%
1 year
19%

Return on equity

10 years
5%
5 years
8%
3 years
9%
Last year
8%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital131314141414151516161616
Reserves424248515238394448566166
Borrowings498993110124118110104131140150160
Other Liabilities5967788671687698116108108134
Minority Interest-0.010.03
Total Liabilities164211233260261238240261311320336376
Fixed Assets525660717071696776808794
CWIP142043020037
Investments000000000722
Other Assets111151172188187164172192235233244272
Total Assets164211233260261238240261311320336376

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity15-19618232227-2232031
Cash from Investing Activity-5-14-8-4-8-5-6-9-22-19-15-21
Cash from Financing Activity-732-640-20-17-1724-1-8-10
Net Cash Flow2-1-81-0-20003-21
Free Cash Flow9-34-2-3-1181918-16121.218.68

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days88105991111051069898113107111110
Inventory Days132145172240217292146162207167238269
Days Payable142163171182147167114143167147189206
Cash Conversion Cycle7887100168175231130117153127161173
Working Capital Days1450264525-111118131264
ROCE %117887-0101210121010

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters525151515151515151515151
FIIs0.140.130.130.130.130.140.140.150.230.140.140.15
DIIs0.90
Public484949494949494949494949
No. of Shareholders15,52915,06014,77215,01416,00715,66715,72315,82615,77415,52015,21414,974

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +12.2% (₹82.93 → ₹93.06)Brick size ₹6.25 (fixed)Bricks 14
₹80.00₹100₹93.06Jan '26Jun '26
Price moved up one brickPrice moved down one brickLast close ₹93.06 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

News

News and filings about Bal Pharma Limited. Open one to see why it matters.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Imported pharmaceutical raw materials
  • Indigenous pharmaceutical raw materials
  • N-Amino Azabicyclo octane (3,3,0) hydrochloride, raw material for Gliclazide
  • Packing materials

Depends on the price of

  • fuel

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE083D01012

Plants

  • Bal Pharma Unit 1 (Formulations), Bommasandra
  • Bal Pharma Unit 2 (API & Intermediates), Bommasandra
  • Bal Pharma Unit 3 (Parenterals), Kenjal
  • Bal Pharma Unit 4 (Formulations), IIE-Pantnagar
  • Bal Pharma Unit 5 (APIs and Intermediates), Kavathe Mahankal
  • Bal Pharma Unit 6 (API and Intermediates), Mewar Industrial Area

News impact

Big market events that reach Bal Pharma Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

17 Sep 2026unspecified₹1.2
18 Sep 2025unspecified₹1.2
18 Sep 2023unspecified₹1
16 Sep 2021unspecified₹1
17 Sep 2019unspecified₹1
14 Sep 2018unspecified₹1
14 Sep 2017unspecified₹1
15 Sep 2016unspecified₹1

Splits, bonuses & buybacks

  • daily-prices repair: 8 rows from NSE's archive (replace 1, delete 0, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
21 Jul 2026ORION STOCKS LTDSELL1,22,544₹89.70
21 Jul 2026ORION STOCKS LTDBUY16,325₹89.69

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.